تجاوز إلى المحتوى الرئيسي

بحث

عنوان الدراسة داعم الدراسة حالة الدراسة دواء الدراسة مرحلة الدراسة رقم بروتوكول الدراسة موقع الدراسة
An Open-lable, Multicenter, expanded access study of INC424 for patients with primary myelofibrosis (PMF) or post polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF). Novartis Ongoing Ruxolitinib 3b CINC424A2401 King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah)
Daily practice treatment and Influence of Visanne on the patient Assessment of quality of life parameters Bayer Completed Visanne 4 VS1101 King Khalid University Hospital (Riyadh), Soliman Fakeeh Hospital (Jeddah)
A Randomized, Open-label, Multicentral, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet) Novartis Ongoing Deferasirox / Defearisox new formula 2 CICL670F2201 King Khalid University Hospital (Riyadh), King Fahad University Hospital (Al-Khobar), King Abdulaziz University Hospital (Jeddah), King Fahad Specialist Hospital (Dammam)
An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting MSD Completed Sitagliptin 4 MK0431-263 Al-Noor Specialist Hospital (Makkah), Armed Forces Hospital (Al-Hada), King Fahad University Hospital (Al-Khobar), Riyadh Care Hospital, Al Alam Medical Center (Riyadh)
A 20-week Study Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients Uncontrolled on NPH Insulin Novonordisk Completed BIAsp 30 / Metformin 4 BIAsp 3968 King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz University Hospital (Jeddah), Armed Forces Hospital (Al-Hada)
A multicentre, prospective observational cohort study to assess the effects of vildagliptin relative to sulphonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan Novartis Completed Vildagliptin / Sulphonylurea / Metformin 4 CLAF237A-MAX-AE-02 Soliman Fakeeh Hospital (Jeddah)
A Multicenter, Prospective, Observational, Non-Interventional Cohort Study Evaluating On-Treatment Predictors of Response in Subjects With HBeAg Positive and HBeAg Negative Chronic Hepatitis B Receiving Therapy With PEGASYS(R) (Peginterferon Alfa-2a 40KD) Roche Completed Pegasys 4 MV22009 King Fahad University Hospital (Al-Khobar), Armed Forces Hospital (Kharj)
A double blind, Double Dummy, Randomized, Multi-Centre study to assess the tolerability and Efficacy Profile of Vildagliptin Compared to Gliclazide as Dual Therapy with Metformin in Muslim Patients with Type 2 Diabetes Fasting During Ramadan. Novartis Completed Vildagliptin /Gliclazide / Metformin 4 CLAF237A2411 King Fahad University Hospital (Al-Khobar)_ King Abdulaziz Medical City NG (Riyadh)
UNraveling nAMD real life Clinical management and Outcome with intraVitrEal Ranibizumab injection – A retrospective analysis (UNCOVER) Novartis Completed Ranibizumab 4 CRFB0021 King Khaled Eye Specialist Hospital (Riyadh)
Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma Roche Completed Bevacizumab 3 MO22923 King Fahad Medical City (Riyadh)_ King Fahad Specialist Hospital (Dammam)
عرض 461 - 470 من 489